Evidence map›Paper›PMID 29459873›Full record

ArticleFrontiers in immunology2018

Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.

Alessandra Gallinaro, Martina Borghi, Roberta Bona, Felicia Grasso, Laura Calzoletti, Laura Palladino, Serena Cecchetti, Maria Fenicia Vescio, Daniele Macchia, Valeria Morante and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Virotherapy as Gene Deliver for Anti-Cancer Therapy: A Review Article.Asian Pacific journal of cancer prevention : APJCP · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Alessandra GallinaroNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Martina BorghiDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Roberta BonaNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Felicia GrassoDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Laura CalzolettiDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Laura PalladinoVisMederi S.r.l., Siena, Italy.
Serena CecchettiConfocal Microscopy Unit NMR, Confocal Microscopy Area Core Facilities, Istituto Superiore di Sanità, Rome, Italy.
Maria Fenicia VescioDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Daniele MacchiaCenter for Animal Research and Welfare, Istituto Superiore di Sanità, Rome, Italy.
Valeria MoranteDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Andrea CanitanoNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Nigel TempertonViral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Kent, United Kingdom.
Maria Rita CastrucciDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Mirella SalvatoreDepartment of Medicine, Weill Cornell Medical College, New York, United States.
Zuleika MicheliniNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Andrea CaraNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Donatella NegriDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Istituto Superiore di Sanità · ITCornell University · USMedway School of Pharmacy · GBVisMederi Research · IT

Funding

Safety and Durability of Integrase Defective Lentiviral vector for an HIV VaccineP01AI110485 · NIAID · DUKE UNIVERSITY · PI KLOTMAN, MARY E. · 2015 to 2019
$9.0M
Multiple Chronic Conditions_Interdisciplinary Nurse Scientist TrainingT32NR015433 · NINR · CASE WESTERN RESERVE UNIVERSITY · PI MOORE, SHIRLEY M · 2015 to 2019
$1.9M
Integrase Defective Lentiviral Vectors for Antibody Delivery against InfluenzaR21AI124141 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI SALVATORE, MIRELLA · 2016 to 2017
$466k
NIAID NIH HHS P01 AI110485NIAID NIH HHS R21 AI124141NINR NIH HHS T32 NR015433
6 · The paper itself

Abstract

Viral vectors represent an attractive technology for vaccine delivery. We exploited the integrase defective lentiviral vector (IDLV) as a platform for delivering relevant antigens within the context of the ADITEC collaborative research program. In particular, Influenza virus hemagglutinin (HA) and nucleoprotein (NP) were delivered by IDLVs while H1N1 A/California/7/2009 subunit vaccine (HAp) with or without adjuvant was used to compare the immune response in a murine model of immunization. In order to maximize the antibody response against HA, both IDLVs were also pseudotyped with HA (IDLV-HA/HA and IDLV-NP/HA, respectively). Groups of CB6F1 mice were immunized intramuscularly with a single dose of IDLV-NP/HA, IDLV-HA/HA, HAp alone, or with HAp together with the systemic adjuvant MF59. Six months after the vaccine prime all groups were boosted with HAp alone. Cellular and antibody responses to influenza antigens were measured at different time points after the immunizations. Mice immunized with HA-pseudotyped IDLVs showed similar levels of anti-H1N1 IgG over time, evaluated by ELISA, which were comparable to those induced by HAp + MF59 vaccination, but significantly higher than those induced by HAp alone. The boost with HAp alone induced an increase of antibodies in all groups, and the responses were maintained at higher levels up to 18 weeks post-boost. The antibody response was functional and persistent overtime, capable of neutralizing virus infectivity, as evaluated by hemagglutination inhibition and microneutralization assays. Moreover, since neuraminidase (NA)-expressing plasmid was included during IDLV preparation, immunization with IDLV-NP/HA and IDLV-HA/HA also induced functional anti-NA antibodies, evaluated by enzyme-linked lectin assay. IFNγ-ELISPOT showed evidence of HA-specific response in IDLV-HA/HA immunized animals and persistent NP-specific CD8+ T cell response in IDLV-NP/HA immunized mice. Taken together our results indicate that IDLV can be harnessed for producing a vaccine able to induce a comprehensive immune response, including functional antibodies directed toward HA and NA proteins present on the vector particles in addition to a functional T cell response directed to the protein transcribed from the vector.

Indexed as

Genetic VectorsAnimalsAntibodies, ViralDisease Models, AnimalDrug Delivery SystemsEnzyme-Linked Immunospot AssayFemaleHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin GInfluenza VaccinesIntegrasesInterferon-gammaLentivirusMiceOrthomyxoviridae InfectionsVaccinationAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin GInfluenza VaccinesIntegrasesInterferon-gammaViral Core Proteinsantibodyinfluenzalentiviral vectorT cell responsevaccine

Identifiers

PMID29459873
PMCPMC5807328
OpenAlexW2792932737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.